JP2006506466A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2006506466A5 JP2006506466A5 JP2005505545A JP2005505545A JP2006506466A5 JP 2006506466 A5 JP2006506466 A5 JP 2006506466A5 JP 2005505545 A JP2005505545 A JP 2005505545A JP 2005505545 A JP2005505545 A JP 2005505545A JP 2006506466 A5 JP2006506466 A5 JP 2006506466A5
- Authority
- JP
- Japan
- Prior art keywords
- substituted
- medicament
- effective amount
- patient
- need
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000003814 drug Substances 0.000 claims 71
- 150000001875 compounds Chemical class 0.000 claims 66
- 239000008194 pharmaceutical composition Substances 0.000 claims 38
- 125000003710 aryl alkyl group Chemical group 0.000 claims 21
- 201000011510 cancer Diseases 0.000 claims 21
- 239000002671 adjuvant Substances 0.000 claims 20
- 230000000240 adjuvant Effects 0.000 claims 20
- 239000003085 diluting agent Substances 0.000 claims 20
- 125000003118 aryl group Chemical group 0.000 claims 19
- 125000000547 substituted alkyl group Chemical group 0.000 claims 17
- 238000004519 manufacturing process Methods 0.000 claims 15
- 125000000217 alkyl group Chemical group 0.000 claims 13
- 239000002246 antineoplastic agent Substances 0.000 claims 13
- 206010053643 Neurodegenerative disease Diseases 0.000 claims 12
- 238000002560 therapeutic procedure Methods 0.000 claims 12
- HCHKCACWOHOZIP-UHFFFAOYSA-N zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 claims 12
- 239000011701 zinc Substances 0.000 claims 12
- 229910052725 zinc Inorganic materials 0.000 claims 12
- 125000001072 heteroaryl group Chemical group 0.000 claims 11
- 229910052739 hydrogen Inorganic materials 0.000 claims 11
- 239000001257 hydrogen Substances 0.000 claims 11
- 208000008589 Obesity Diseases 0.000 claims 10
- 239000000883 anti-obesity agent Substances 0.000 claims 10
- 125000004404 heteroalkyl group Chemical group 0.000 claims 10
- 125000004446 heteroarylalkyl group Chemical group 0.000 claims 10
- 235000020824 obesity Nutrition 0.000 claims 10
- 125000000753 cycloalkyl group Chemical group 0.000 claims 9
- 150000002431 hydrogen Chemical class 0.000 claims 9
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 9
- 239000012453 solvate Substances 0.000 claims 9
- 229910015800 MoS Inorganic materials 0.000 claims 8
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 8
- 125000003342 alkenyl group Chemical group 0.000 claims 7
- 125000003107 substituted aryl group Chemical group 0.000 claims 7
- 206010064930 Age-related macular degeneration Diseases 0.000 claims 6
- 206010001897 Alzheimer's disease Diseases 0.000 claims 6
- 206010002026 Amyotrophic lateral sclerosis Diseases 0.000 claims 6
- 206010006187 Breast cancer Diseases 0.000 claims 6
- 208000005243 Chondrosarcoma Diseases 0.000 claims 6
- 206010009944 Colon cancer Diseases 0.000 claims 6
- 208000001258 Hemangiosarcoma Diseases 0.000 claims 6
- 208000003055 Prion Disease Diseases 0.000 claims 6
- 206010060862 Prostate cancer Diseases 0.000 claims 6
- 206010038389 Renal cancer Diseases 0.000 claims 6
- 206010039073 Rheumatoid arthritis Diseases 0.000 claims 6
- 208000000208 Wet Macular Degeneration Diseases 0.000 claims 6
- 230000033115 angiogenesis Effects 0.000 claims 6
- 201000003076 angiosarcoma Diseases 0.000 claims 6
- 201000005216 brain cancer Diseases 0.000 claims 6
- RYGMFSIKBFXOCR-UHFFFAOYSA-N copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 claims 6
- 229910052802 copper Inorganic materials 0.000 claims 6
- 239000010949 copper Substances 0.000 claims 6
- 201000010982 kidney cancer Diseases 0.000 claims 6
- 125000005346 substituted cycloalkyl group Chemical group 0.000 claims 6
- 230000002159 abnormal effect Effects 0.000 claims 5
- 125000004474 heteroalkylene group Chemical group 0.000 claims 4
- UFHFLCQGNIYNRP-UHFFFAOYSA-N hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 2
- 125000000954 2-hydroxyethyl group Chemical group [H]C([*])([H])C([H])([H])O[H] 0.000 claims 1
- 208000002780 Macular Degeneration Diseases 0.000 claims 1
- JUJWROOIHBZHMG-UHFFFAOYSA-O Pyridinium Chemical class C1=CC=[NH+]C=C1 JUJWROOIHBZHMG-UHFFFAOYSA-O 0.000 claims 1
- 230000001594 aberrant Effects 0.000 claims 1
- 239000004480 active ingredient Substances 0.000 claims 1
- 125000004350 aryl cycloalkyl group Chemical group 0.000 claims 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 125000006448 cycloalkyl cycloalkyl group Chemical group 0.000 claims 1
- RAXXELZNTBOGNW-UHFFFAOYSA-O imidazolium Chemical compound C1=C[NH+]=CN1 RAXXELZNTBOGNW-UHFFFAOYSA-O 0.000 claims 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims 1
- RWRDLPDLKQPQOW-UHFFFAOYSA-O pyrrolidinium Chemical compound C1CC[NH2+]C1 RWRDLPDLKQPQOW-UHFFFAOYSA-O 0.000 claims 1
- 125000005017 substituted alkenyl group Chemical group 0.000 claims 1
- 0 CC[N+](CC)(CC)CCCCC*CC*CC[N+](CC)(CC)CC Chemical compound CC[N+](CC)(CC)CCCCC*CC*CC[N+](CC)(CC)CC 0.000 description 11
- ZNEOHLHCKGUAEB-UHFFFAOYSA-N C[N+](C)(C)c1ccccc1 Chemical compound C[N+](C)(C)c1ccccc1 ZNEOHLHCKGUAEB-UHFFFAOYSA-N 0.000 description 2
- JBKPUQTUERUYQE-UHFFFAOYSA-O C[n+]1c(/C=N\O)cccc1 Chemical compound C[n+]1c(/C=N\O)cccc1 JBKPUQTUERUYQE-UHFFFAOYSA-O 0.000 description 2
- JWLVVWBHILZADA-UHFFFAOYSA-N CC(CC[N+](C)(C)C)O Chemical compound CC(CC[N+](C)(C)C)O JWLVVWBHILZADA-UHFFFAOYSA-N 0.000 description 1
- OIPILFWXSMYKGL-UHFFFAOYSA-N CC(OCC[N+](C)(C)C)=O Chemical compound CC(OCC[N+](C)(C)C)=O OIPILFWXSMYKGL-UHFFFAOYSA-N 0.000 description 1
- YUVRFZXUICLHML-UHFFFAOYSA-N CCC(CC)(CC[N+](C)(C)C)C[N](C)(C)C Chemical compound CCC(CC)(CC[N+](C)(C)C)C[N](C)(C)C YUVRFZXUICLHML-UHFFFAOYSA-N 0.000 description 1
- IBZJNLWLRUHZIX-UHFFFAOYSA-N CCN1C=CN(C)C1 Chemical compound CCN1C=CN(C)C1 IBZJNLWLRUHZIX-UHFFFAOYSA-N 0.000 description 1
- MFDFERRIHVXMIY-UHFFFAOYSA-O CC[NH+](CC)CCOC(c(cc1)ccc1N)=O Chemical compound CC[NH+](CC)CCOC(c(cc1)ccc1N)=O MFDFERRIHVXMIY-UHFFFAOYSA-O 0.000 description 1
- WYFGXQCOMIYMIE-UHFFFAOYSA-N C[N+](C)(C)C1CC1 Chemical compound C[N+](C)(C)C1CC1 WYFGXQCOMIYMIE-UHFFFAOYSA-N 0.000 description 1
- AACHVWXCVWWMSI-UHFFFAOYSA-N C[N+](C)(C)CCCO Chemical compound C[N+](C)(C)CCCO AACHVWXCVWWMSI-UHFFFAOYSA-N 0.000 description 1
- JMIXRFUTQFPCLN-UHFFFAOYSA-N C[N+](C)(C)CCCOCCOC Chemical compound C[N+](C)(C)CCCOCCOC JMIXRFUTQFPCLN-UHFFFAOYSA-N 0.000 description 1
- NJICVKXEONIFAZ-UHFFFAOYSA-N C[N+](C)(C)CCOCCOC Chemical compound C[N+](C)(C)CCOCCOC NJICVKXEONIFAZ-UHFFFAOYSA-N 0.000 description 1
- BBTHTWPHAAPRGI-UHFFFAOYSA-N C[N+](C)(CCC1OCC1)Cc1ccccc1 Chemical compound C[N+](C)(CCC1OCC1)Cc1ccccc1 BBTHTWPHAAPRGI-UHFFFAOYSA-N 0.000 description 1
- ZHYRZMGVDRAROM-UHFFFAOYSA-O C[NH+](C)CCC1[O](CC[O](CC[N+](C)(C)C)=C)C1 Chemical compound C[NH+](C)CCC1[O](CC[O](CC[N+](C)(C)C)=C)C1 ZHYRZMGVDRAROM-UHFFFAOYSA-O 0.000 description 1
- PAFZNILMFXTMIY-UHFFFAOYSA-O [NH3+]C1CCCCC1 Chemical compound [NH3+]C1CCCCC1 PAFZNILMFXTMIY-UHFFFAOYSA-O 0.000 description 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US10/202,346 US20040019043A1 (en) | 2002-07-23 | 2002-07-23 | Thiomolybdate analogues and uses thereof |
| US43474202P | 2002-12-18 | 2002-12-18 | |
| US43695803A | 2003-05-12 | 2003-05-12 | |
| US10/447,585 US7189865B2 (en) | 2002-07-23 | 2003-05-28 | Thiomolybdate analogues and uses thereof |
| PCT/US2003/023031 WO2004009034A2 (en) | 2002-07-23 | 2003-07-22 | Thiomolybdate analogues and uses thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2006506466A JP2006506466A (ja) | 2006-02-23 |
| JP2006506466A5 true JP2006506466A5 (hu) | 2006-09-14 |
Family
ID=30773643
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2005505545A Pending JP2006506466A (ja) | 2002-07-23 | 2003-07-22 | チオモリブデン酸類似物及びそれらの使用 |
Country Status (19)
| Country | Link |
|---|---|
| US (1) | US7189865B2 (hu) |
| EP (1) | EP1556029B1 (hu) |
| JP (1) | JP2006506466A (hu) |
| KR (1) | KR20050053596A (hu) |
| CN (1) | CN100531732C (hu) |
| AU (1) | AU2003256704A1 (hu) |
| BR (1) | BR0312851A (hu) |
| CA (1) | CA2493127A1 (hu) |
| DK (1) | DK1556029T3 (hu) |
| EA (1) | EA200500250A1 (hu) |
| ES (1) | ES2448800T3 (hu) |
| HR (1) | HRP20050174A2 (hu) |
| IL (1) | IL166448A0 (hu) |
| MX (1) | MXPA05000870A (hu) |
| NO (1) | NO20050917L (hu) |
| PL (1) | PL374821A1 (hu) |
| PT (1) | PT1556029E (hu) |
| SI (1) | SI1556029T1 (hu) |
| WO (1) | WO2004009034A2 (hu) |
Families Citing this family (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2000018392A1 (en) * | 1998-09-25 | 2000-04-06 | Glycox Corporation Limited | Fructosamine oxidase: antagonists and inhibitors |
| CA2371625C (en) * | 1999-04-30 | 2012-04-17 | Slil Biomedical Corporation | Polyamines and their use in therapy |
| CA2368801A1 (en) * | 1999-04-30 | 2000-11-09 | Slil Biomedical Corporation | Conjugates as therapies for cancer and prostate diseases |
| EP1337504A4 (en) * | 2000-11-08 | 2005-10-05 | Cellgate Inc | NOVEL AMINO ACID CONJUGATES AND POLYAMINE ANALOGUES USEFUL AS ANTICANCING AGENTS |
| JP2005504060A (ja) * | 2001-08-24 | 2005-02-10 | メイン・メデイカル・センター・リサーチ・インステイテユート | 銅依存性の非伝統的前炎症性サイトカイン輸送およびそれに関連する方法、組成物およびキット |
| AU2002340224B2 (en) * | 2001-10-16 | 2008-11-27 | Progen Pharmaceuticals, Inc | Oligoamine compounds and derivatives thereof for cancer therapy |
| EP2500018B1 (en) * | 2002-03-08 | 2017-07-19 | PhilERA New Zealand Limited | Preventing and/or Treating Cardiovascular Disease and/or Associated Heart Failure |
| EP1531827A4 (en) * | 2002-05-24 | 2009-07-08 | Univ Michigan | COPPER-REDUCING TREATMENT FOR INFLAMMATORY AND FIBROTIC DISEASES |
| AU2003261222B2 (en) * | 2002-07-23 | 2009-07-09 | The Regents Of The University Of Michigan | Tetrapropylammonium tetrathiomolybdate and related compounds for anti-angiogenic therapies |
| CA2496411A1 (en) | 2002-08-20 | 2004-03-04 | Protemix Corporation Limited | Dosage forms and related therapies |
| US7851505B2 (en) | 2003-05-27 | 2010-12-14 | Attenuon, Llc | Thiotungstate analogues and uses thereof |
| WO2005082382A1 (en) * | 2004-02-23 | 2005-09-09 | Attenuon Llc | Formulations of thiomolybdate or thiotungstate compounds and uses thereof |
| AU2005217623A1 (en) * | 2004-02-24 | 2005-09-09 | Attenuon Llp | Inhibition of superoxide dismutase by tetrathiomolybdate: identification of new anti-angiogenic and antitumor agents |
| CA2577634C (en) | 2004-07-19 | 2015-07-07 | Protemix Corporation Limited | Synthesis of triethylenetetramines |
| JP5099620B2 (ja) * | 2006-10-26 | 2012-12-19 | 学校法人日本大学 | 筋萎縮性側索硬化症治療薬 |
| WO2008103421A1 (en) * | 2007-02-21 | 2008-08-28 | Ssv Therapeutics, Inc. | Adamantanamines and neramexane salts of thiomolybdic and thiotungstic acids |
| PL381862A1 (pl) | 2007-02-28 | 2008-09-01 | Trigendo Spółka Z Ograniczoną Odpowiedzialnością | Zastosowanie związków pirydyniowych i sposób leczenia |
| US20090028800A1 (en) * | 2007-07-27 | 2009-01-29 | Peeples William H | Method of Treating Postpartum Depression and Aggression |
| US20110028513A1 (en) * | 2008-03-31 | 2011-02-03 | Lang Zhuo | Method for treating neurological disorders with imidazolium and imidazolinium compounds |
| JP6285164B2 (ja) * | 2013-12-05 | 2018-02-28 | デクセリアルズ株式会社 | 化合物、熱硬化性樹脂組成物、及び熱硬化性シート |
| WO2017146939A1 (en) * | 2016-02-23 | 2017-08-31 | Vanderbilt Chemicals, Llc | Quaternary ammonium sulfur-containing binuclear molybdate salts as lubricant additives |
| EP4029498A1 (en) * | 2017-12-04 | 2022-07-20 | Alexion Pharmaceuticals, Inc. | Bis-choline tetrathiomolybdate for treating wilson disease |
| US11419832B2 (en) * | 2017-12-04 | 2022-08-23 | Alexion Pharmaceuticals, Inc. | Bis-choline tetrathiomolybdate for treating Wilson Disease |
| US11739051B2 (en) | 2018-02-06 | 2023-08-29 | Alexion Pharmaceuticals, Inc. | Crystalline particles of bis-choline tetrathiomolybdate |
| JP7394773B2 (ja) * | 2018-02-15 | 2023-12-08 | アレクシオン・ファーマ・インターナショナル・オペレーションズ・リミテッド | ビス－コリンテトラチオモリブデートの製造方法 |
| EP3911604A2 (en) | 2019-01-14 | 2021-11-24 | Alexion Pharmaceuticals, Inc. | Methods for preparing ammonium tetrathiomolybdate |
| US11471497B1 (en) | 2019-03-13 | 2022-10-18 | David Gordon Bermudes | Copper chelation therapeutics |
| CN116528920A (zh) | 2020-10-07 | 2023-08-01 | Cti血管公司 | 可生物活化的装置和相关方法 |
| WO2022165339A1 (en) * | 2021-01-31 | 2022-08-04 | Alexion Pharmaceuticals, Inc. | Novel formulation for treating copper metabolism-associated diseases or disorders |
| US20230226105A1 (en) * | 2021-11-10 | 2023-07-20 | Reverspah Llc | Methods and compositions for treating cancer |
| CN114042083B (zh) * | 2021-12-06 | 2022-08-30 | 湖南师范大学 | 四硫代钼酸盐的增肌及治疗应用 |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2909541A (en) * | 1955-01-07 | 1959-10-20 | Inst Francais Du Petrole | Nitrogenous thiomolybdates |
| US3845770A (en) * | 1972-06-05 | 1974-11-05 | Alza Corp | Osmatic dispensing device for releasing beneficial agent |
| US3916899A (en) * | 1973-04-25 | 1975-11-04 | Alza Corp | Osmotic dispensing device with maximum and minimum sizes for the passageway |
| US4400282A (en) | 1980-12-05 | 1983-08-23 | Gulf Research & Development Company | Lubricating oils containing quaternary ammonium thiomolybdates |
| US4343746A (en) * | 1980-12-10 | 1982-08-10 | Gulf Research & Development Company | Quaternary ammonium thiomolybdates |
| US4430443A (en) * | 1982-07-20 | 1984-02-07 | Exxon Research And Engineering Co. | Supported carbon-containing molybdenum and tungsten sulfide catalysts, their preparation and use |
| GB8504253D0 (en) * | 1985-02-19 | 1985-03-20 | Ici Plc | Electrostatic spraying apparatus |
| DE3815221C2 (de) * | 1988-05-04 | 1995-06-29 | Gradinger F Hermes Pharma | Verwendung einer Retinol- und/oder Retinsäureester enthaltenden pharmazeutischen Zubereitung zur Inhalation zur Einwirkung auf die Schleimhäute des Tracheo-Bronchialtraktes einschließlich der Lungenalveolen |
| US5698155A (en) * | 1991-05-31 | 1997-12-16 | Gs Technologies, Inc. | Method for the manufacture of pharmaceutical cellulose capsules |
| US5639725A (en) * | 1994-04-26 | 1997-06-17 | Children's Hospital Medical Center Corp. | Angiostatin protein |
| WO1996028205A1 (en) * | 1995-03-14 | 1996-09-19 | Siemens Aktiengesellschaft | Ultrasonic atomizer device with removable precision dosing unit |
| ES2140069T3 (es) * | 1995-03-14 | 2000-02-16 | Siemens Ag | Dispositivo atomizador ultrasonico con unidad dosificadora de precision desmontable. |
| US6953557B1 (en) | 1997-10-17 | 2005-10-11 | Ebara Corporation | Process and apparatus for treating semiconductor production exhaust gases |
| US5954047A (en) * | 1997-10-17 | 1999-09-21 | Systemic Pulmonary Development, Ltd. | Methods and apparatus for delivering aerosolized medication |
| PT1107795E (pt) * | 1998-09-04 | 2003-04-30 | Univ Michigan | Tiomolibdato associado com pelo menos um hidrato de carbono e o seu uso para evitar ou tratar doencas caracterizadas por uma vascularizacao tais como cancro degeneracao macular do tipo humido artrite reumatoide |
| CN1262226A (zh) | 1999-12-03 | 2000-08-09 | 中国科学院兰州化学物理研究所 | 硫代钼酸盐及其制备方法和用途 |
| EP1531827A4 (en) * | 2002-05-24 | 2009-07-08 | Univ Michigan | COPPER-REDUCING TREATMENT FOR INFLAMMATORY AND FIBROTIC DISEASES |
| AU2003261222B2 (en) * | 2002-07-23 | 2009-07-09 | The Regents Of The University Of Michigan | Tetrapropylammonium tetrathiomolybdate and related compounds for anti-angiogenic therapies |
-
2003
- 2003-05-28 US US10/447,585 patent/US7189865B2/en not_active Expired - Lifetime
- 2003-07-22 ES ES03765973.7T patent/ES2448800T3/es not_active Expired - Lifetime
- 2003-07-22 MX MXPA05000870A patent/MXPA05000870A/es active IP Right Grant
- 2003-07-22 PT PT37659737T patent/PT1556029E/pt unknown
- 2003-07-22 KR KR1020057001310A patent/KR20050053596A/ko not_active Application Discontinuation
- 2003-07-22 SI SI200332340T patent/SI1556029T1/sl unknown
- 2003-07-22 EA EA200500250A patent/EA200500250A1/ru unknown
- 2003-07-22 JP JP2005505545A patent/JP2006506466A/ja active Pending
- 2003-07-22 BR BR0312851-2A patent/BR0312851A/pt not_active IP Right Cessation
- 2003-07-22 AU AU2003256704A patent/AU2003256704A1/en not_active Abandoned
- 2003-07-22 EP EP03765973.7A patent/EP1556029B1/en not_active Expired - Lifetime
- 2003-07-22 PL PL03374821A patent/PL374821A1/xx not_active Application Discontinuation
- 2003-07-22 WO PCT/US2003/023031 patent/WO2004009034A2/en active Application Filing
- 2003-07-22 DK DK03765973.7T patent/DK1556029T3/en active
- 2003-07-22 CA CA002493127A patent/CA2493127A1/en not_active Abandoned
- 2003-07-22 CN CNB038225557A patent/CN100531732C/zh not_active Expired - Lifetime
-
2005
- 2005-01-23 IL IL16644805A patent/IL166448A0/xx unknown
- 2005-02-21 NO NO20050917A patent/NO20050917L/no not_active Application Discontinuation
- 2005-02-22 HR HR20050174A patent/HRP20050174A2/hr not_active Application Discontinuation
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2006506466A5 (hu) | ||
| CN106715415B (zh) | 3-氨基-1,5,6,7-四氢-4h-吲哚-4-酮 | |
| TWI699359B (zh) | ４ｈ-吡咯［３,２-ｃ］吡啶-４-酮衍生物 | |
| AU766056B2 (en) | Calcium (3s) tetrahydro-3-furanyl(1s,2r)-3-(((4-aminophenyl) sulfonyl) (isobutyl) amino) -1-benzyl-2- (phosphonooxy) propylcarbamate | |
| JP2005526723A5 (hu) | ||
| JP2005535698A5 (hu) | ||
| JP2020503341A5 (hu) | ||
| CN110461853A (zh) | 苯并噻吩雌激素受体调节剂 | |
| CA3082735A1 (en) | Substituted macrocyclic indole derivatives | |
| JP2019526546A5 (hu) | ||
| KR102303052B1 (ko) | Jak 저해제를 포함하는 제약 조성물 | |
| US20210292341A1 (en) | Macrocyclic indole derivatives | |
| UA121482C2 (uk) | Комбінація інгібітору протеасом, яким є бортезоміб, та інгібітору c-met для лікування множинної мієломи | |
| JP2019536755A (ja) | 金属供給源、ジチオカルバメート及びシクロデキストリンを含む組成物 | |
| JP2019533660A5 (hu) | ||
| JP2007516234A5 (ja) | チオタングステートアナログ及びその使用 | |
| JP2006518731A5 (hu) | ||
| JP2007521313A5 (hu) | ||
| WO2015127284A2 (en) | Antimitotic amides for the treatment of cancer and proliferative disorders | |
| JP5210888B2 (ja) | 黒色腫の治療のためのガリウム（ｉｉｉ）錯体の使用 | |
| CN101361741A (zh) | 异噁唑啉类衍生物抗肿瘤新用途 | |
| JP2004517151A5 (hu) | ||
| CN108586443A (zh) | 一种防治支气管肺癌的药物及其制备方法 | |
| RU2018141584A (ru) | Триазолы для регуляции гомеостаза внутриклеточного кальция | |
| JP2018536716A5 (hu) |